Event-Driven Stocks

Minerva Neurosciences, Inc.

NERVNasdaq

Healthcare · Pharmaceutical Preparations · MA · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 2 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue—$0$0$0$0$41.2M
Operating income−$15.1M−$21.8M−$23.1M−$25.2M−$45.4M$1.8M
Net income−$293.4M$1.4M−$30.0M−$32.1M−$49.9M$1.9M
Total assets$98.0M$37.1M$56.9M$55.1M$77.1M$57.6M
Total liabilities$233.8M$62.8M$85.4M$75.1M$69.1M$5.0M
Equity−$140.7M−$25.7M−$28.5M−$20.0M$8.0M$52.7M
EPS (diluted)$-34.67$0.19$-4.61$-6.01$-1.17$0.05
Shares out.7.0M7.0M5.3M42.7M42.7M39.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
208.5%
Return on assets
−299.5%
Return on capital (ROCE)
−15.8%
Liabilities / assets
238.6%
Debt / equity
—
Book value / share
$-20.13
Revenue growth (YoY)
—
Net income growth (YoY)
−20492.7%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-19.18distress
Accruals / assets
−285.7%clean
Piotroski F-Score
3/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
32
/ 100
Profitability 33Growth 0Catalyst 33Earnings quality 67Financial strength 25

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 2 severe● 2 warning● 2 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.2M10.7-10.6%
Apr 30, 20261.3M7.9+14.8%
Apr 15, 20261.2M5.1+13.3%
Mar 31, 20261.0M1.9+82.5%
Mar 13, 2026559,5302.0+27.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.